Edit

Touchlight

https://www.touchlight.com/

Last activity: 17.09.2026

Active

Categories: DevelopmentFutureHealthTechHouseIndustryMovingPlatformProductionServiceTechnology

At Touchlight we are revolutionising DNA.

Our Company and technology is built on the conviction that DNA is fundamental to the future of medicine.

By moving away from today's restrictive biological approaches, we have made DNA simple. Our unique dbDNA™ (or "doggybone" DNA) vector is optimised for use in advanced genetic medicines, being safer and more efficacious than conventional plasmid DNA. The platform, based on enzymatic technology, enable DNA production at unprecedented scale, speed and purity.

We are leveraging our platform to develop the next generation of DNA vaccines for oncology and infectious diseases, in house and in collaboration with industry partners and academics, as well as enabling manufacture of advanced therapies (viral vectors, mRNA vaccines, and cell therapies) through our CDMO, Touchlight DNA Services.

For more information please visit our website or get in touch by emailing info@touchlight.com.

Website visits

6.7K /mo.

Mentions

Employees: 51-200

Founded date: 2008

Investors 1

Date	Name	Website
31.08.2021	Novator Pa...	novator.co...

Mentions in press and media 23

Date	Title	Description
17.09.2026	What Synthetic Biology Actually Means for Everyday Life	While it may sound like something that only happens in a lab, you will actually find applications of synthetic biology in your supermarket, as well as your clothing and medicine cabinet. At its core, synthetic biology is the application of ...
01.12.2022	Touchlight Receives Grant From Bill & Melinda Gates Foundation	Touchlight, a London, UK-based biotechnology company, received a grant from Bill & Melinda Gates Foundation. The amount of the grant was not disclosed. The funding builds on preclinical data showing the potential of nanoparticle-formula...
14.11.2022	AAV Manufacturing — Overcoming the Challenges of Plasmid DNA, Upcoming Webinar Hosted by Xtalks	This includes slow or delayed production and poor DNA quality (owing to unstable or difficult sequences), impacting their ability to meet drug development timelines and regulatory demands. TORONTO (PRWEB) November 14, 2022 AAV manufacturing...
08.03.2022	With investment from Alloy, Boston peptide manufacturer announces Series A	What’s another £100 million when you’ve already gone three times over budget? Just another rounding number for AstraZeneca, which is still running up the tab on its gleaming new R&D/HQ in Cambridge, UK. The Times spotlighted the fresh o...
08.03.2022	Kurma scores $175M in first closing of biotech/healthtech fund — the VC's largest yet	Biogen CEO Michel Vounatsos is betting on success. But he’s keeping one hand firmly on the budget axe in case the cards stay cold. And he’s ready to chop as hard as necessary to keep the bottom line in shape. In a fireside chat on Monday du...
08.03.2022	With investment from Alloy, Boston peptide manufacturer announces Series A	In an ideal scenario, Mytide Therapeutics co-founder Dale Thomas pictures his company’s tech in hospitals across America. On Tuesday, the company announced a $7 million Series A fundraising round that will help bring that goal a step closer...
08.03.2022	BioNTech and Regeneron expand their cancer partnership, pushing new Libtayo combo into NSCLC	There was a single question conspicuously absent in all the discussion over last week’s CRISPR patent ruling (a single number, really): How much are the patents actually worth? The US Patent and Trademark Office ruling, after years of legal...
08.03.2022	With investment from Alloy, Boston peptide manufacturer announces Series A	Butts, bums and booties star in Endo’s first campaign for cellulite busting injectable Qwo. Shown dancing, walking on the beach, and exercising in the yoga studio, the “Butt First” campaign visually and through its voiceover, reminds women ...
08.03.2022	With investment from Alloy, Boston peptide manufacturer announces Series A	For bluebird bio, the FDA’s verdict on its gene therapies — slated for August and September, respectively — could be a life-or-death decision. The biotech, once a high-flying Wall Street darling that represented a new, flashy breed of drug ...
08.03.2022	With investment from Alloy, Boston peptide manufacturer announces Series A	First approved by the FDA in 2006, Bristol Myers Squibb’s cash cow cancer drug Revlimid on Monday began seeing competition for the first time with a Teva generic. Acquired as part of BMS’ $74 billion buyout of Celgene in 2019, the multiple ...
08.03.2022	BioNTech and Regeneron expand their cancer partnership, pushing new Libtayo combo into NSCLC	After going back to the negotiating table, BioNTech and Regeneron have come away with an expanded collaboration pushing their efforts into lung cancer. The two built upon a previous deal in which researchers evaluated the PD-1 antibody Libt...
08.03.2022	BioNTech and Regeneron expand their cancer partnership, pushing new Libtayo combo into NSCLC	Whatever Voyager is coming up with on its new gene therapy platform, Novartis wants a piece of it. Voyager, which pivoted back into discovery last year following a streak of setbacks on its clinical efforts, is set to receive $54 million up...
07.03.2022	Months after big financing round, Touchlight signs supply agreement for Versameb's pipeline	A UK-based CDMO has landed a supply agreement with Versameb to provide its doggybone DNA for the company’s pipeline, including for its lead candidate to treat stress urinary incontinence. Touchlight will supply Versameb with its enzymatic D...
07.03.2022	After nearly two years of criticism from activists and White House, Moderna unveils a new plan for global health	Moderna, the target of nearly two years of criticism for its policies around global access to its Covid-19 vaccine, announced on Monday a new plan to address global health. The mRNA biotech said it would launch a four-part program. First, i...
07.03.2022	J&J regrets paying for study that injected incarcerated Black men with asbestos — report	Newly unsealed court documents reveal that Johnson & Johnson paid for a study that injected 10 incarcerated Black men with asbestos, as part of the company’s early talcum powder trials, according to a new report in Bloomberg News. Alber...
07.03.2022	GSK chief Emma Walmsley made $10.8M last year, lagging far behind fellow Big Pharma CEOs	GlaxoSmithKline chief Emma Walmsley — Big Pharma’s first female CEO — saw a significant pay raise last year amid “strong sales and performance,” in part due to the company’s Covid antibody sales. But even so, her pay package still falls far...
07.03.2022	Kenya wins $500M sweepstakes for Moderna's first African manufacturing site	After a long wait, Moderna now has a home for its first manufacturing site in Africa. The biotech entered a memorandum of understanding with the Kenyan government to finalize the country as the site for the country’s first manufacturing ope...
09.02.2022	Bayer - AskBio and Touchlight Restructure Joint Venture	Research Triangle Park, N.C. and Hampton, UK - Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, and Touchlight, a biotechnology company pioneering enzyma...
18.12.2020	Immune Regulation makes Peter Greenleaf chairman and assembles a quintet of new execs; Bob Coughlin moves on from MassBio to JLL	Peter Greenleaf → In September, Immune Regulation raked in $53.4 million in a Series B for two programs in rheumatoid arthritis and asthma. This week, the British biotech has named Aurinia CEO Peter Greenleaf chairman of t...
09.11.2018	One year in, Joanne Kotz assumes CEO role at Jnana; President/Executive chair duo will now run BlackThorn	Joanne Kotz → Jnana Therapeutics is marking its anniversary with the installation of a permanent chief, and it’s going for someone who’s been there since the beginning: co-founder and president Joanne Kotz. Amir Nashat, the...
-	The time to put the spotlight on Healthcare is now	As Covid-19 continues to dominate the global agenda, early-stage UK technology companies in the healthcare and life sciences sectors are at the forefront of making the world a safer and more secure place to live in. The need for accelera...
-	Downing Ventures portfolio creating positive impact through the pandemic	This has been an unprecedented year on every level with the appearance of Covid-19. Individuals, families, countries, institutions, companies, big and small, have all been impacted and the world has had to pull together to get through one o...
-	How to survive and thrive in 2021 as a VC firm according to Downing Ventures	In 2021, it has never been more important for venture capital firms to be able to differentiate. The success of a VC fund is based on their ability to successfully identify and gain access to the highest quality companies and crucially, th...

Touchlight

Investors 1

Mentions in press and media 23

Reviews 0